IPCA Laboratories share price
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
IPCA Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Feb 1995 on NSE
Last close ₹1,930.50down ₹50.30 (2.54%)BSE ₹1,928.45
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,980.80.
28 Oct: open ₹1,980.00, high ₹1,988.50, low ₹1,920.10
52-week range of traded prices to 28 Oct 2026
₹1,268.00Low, 31 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹48,978 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,75,48945.2% delivered
About IPCA Laboratories
IPCA Laboratories Limited is a Mumbai-based drug company that develops, makes and markets branded and generic medicines and active pharmaceutical ingredients (APIs, the chemical raw material of medicines).1 It sells in India and abroad, to wholesalers, distributors, pharmacy chains, hospitals, government institutions and other drug companies.21
It makes and markets over 350 formulations (finished medicines) and 80 APIs across therapy areas, and its products are sold in over 100 countries.3 Exports are over 42% of its standalone revenue, that is, the company's own sales without its subsidiaries.4 In India it sells through about 7,000 medical representatives; abroad it promotes its own brands through field forces in Africa and Asian countries such as Nepal, Sri Lanka and Vietnam.56 In the US its step-down subsidiary Unichem Pharmaceuticals (USA) distributes the medicines it makes, and in the United Kingdom it sells generics under its own label.67 It has 16 manufacturing units in India, and 23 together with its subsidiaries.89
It was incorporated in 1949.10 It holds 52.67% of Unichem Laboratories, its one listed Indian subsidiary.111213 Its promoters, who held 44.72% of the shares in its filing of 26 Jun 2026, include Executive Chairman Premchand Godha and his sons Pranay Godha, Managing Director and CEO, and Prashant Godha, Executive Director.141516
IPCA Laboratories key points
Results
- In the quarter to Jun 2026, consolidated total income was ₹2,813.36 crore, up 20% from ₹2,341.51 crore a year earlier, and profit after tax was ₹401.89 crore, up 72%.17
- Consolidated EBITDA (earnings before interest, tax, depreciation and amortisation) for the quarter was about ₹638 crore, against ₹425 crore, a margin of 22.88% against 18.39%.18
- In the year to Mar 2026, consolidated total income rose 8.73% to ₹9,820.78 crore from ₹9,032.39 crore.19
- For that year, consolidated earnings before interest, depreciation, tax and one-off items were ₹2,153.01 crore, against ₹1,818.94 crore, and net profit after one-off items rose 51.28% to ₹1,191.37 crore from ₹787.53 crore.20
Market position
- It ranked 16th in the Indian medicine market in the year to June 2026, by sales data from IQVIA, a research firm, with a market share of about 2.08% against 2.07% in March 2026.2122
- 6 of its brands are among India's 300 top-selling medicine brands: Zerodol-SP, Zerodol-P, HCQS, Folitrax, CTD-T and Zerodol TH.2324
Revenue mix
- Standalone sales by business2526Nearly 75% of API and intermediate sales are exports.
Item year to Mar 2026 year to Mar 2025 Branded medicines, India ₹3,817.24 crore ₹3,450.21 crore Generic and tender medicines, exports ₹1,418.91 crore ₹1,336.69 crore APIs and intermediates ₹1,395.74 crore ₹1,265.84 crore Branded medicines, exports ₹663.67 crore ₹581.89 crore - Non-steroidal anti-inflammatory drugs (NSAIDs, common painkillers) were 53% of its domestic branded sales in the year to Mar 2026, as a year earlier.27
- In the quarter to Jun 2026, domestic formulation sales grew 13% to about ₹1,082 crore from ₹961 crore, and API sales grew about 30% to about ₹424 crore from ₹362 crore.28
Where revenue comes from
- Standalone exports by region293031Total exports were ₹3,129.43 crore, against ₹2,808.96 crore.
Item year to Mar 2026 year to Mar 2025 Europe ₹884.59 crore ₹806.11 crore Americas ₹665.33 crore ₹536.00 crore Africa ₹594.48 crore ₹545.70 crore Asia, excluding India ₹398.17 crore ₹391.86 crore Australasia ₹317.68 crore ₹283.03 crore CIS (former Soviet states) ₹269.18 crore ₹246.26 crore
Plants and capacity
- A new API and drug intermediates plant at Hingni, Wardha district, Maharashtra, built for ₹182 crore, began commercial production in February 2026.32
- The company stated in its annual report for the year to Mar 2026 that it is building a formulations plant at Dewas, Madhya Pradesh, at about ₹275 crore, for trial production in the year to Mar 2027.33
- The company stated in its annual report for the year to Mar 2026 that its US subsidiary Pisgah Laboratories is building a liquids and injectables plant in North Carolina at about $22 million, for trial production in the year to Mar 2027.34
Research and development
- It has R&D centres at Mumbai, Ratlam, Athal (Silvassa) and Ranu (Vadodara) and over 650 scientists, and has filed 287 patent applications.3536
- In the US it has filed 47 ANDAs (applications to sell a generic medicine), of which 33 are approved, and 50 drug master files (dossiers on how an API is made).3738
- For biosimilars (near-copies of biological medicines), it has set up a monoclonal antibody plant at Pithampur at about ₹250 crore, and a bio-manufacturing facility with 500 and 2,000 litre capacity.3940
What the company expects
- On its earnings call of 14 Aug 2026, the company said it expects business growth of about 14% to 16% in the year to Mar 2027, raised from 12% to 13%, and a consolidated EBITDA margin of about 23%, raised from 22%.41
- On its earnings call of 14 Aug 2026, the company said it expects capital spending of about ₹700 crore to ₹800 crore in the year to Mar 2027, partly on new API plants at Dewas and Wardha as Ratlam runs out of capacity.42
- On its earnings call of 14 Aug 2026, the company said it plans to invest about ₹100 crore more this year in biotech pilot facilities and R&D, with clinical work on its biosimilars starting next financial year.4344
Recent events
- On 7 Jul 2026, India Ratings & Research affirmed its credit ratings (the agency's view of its ability to repay): IND AA+/Stable on ₹22,481.10 million of bank loan facilities and IND A1+ on commercial paper.4546
- On 26 Jun 2026, the board approved merging Krebs Biochemicals & Industries, a maker of fermentation-based APIs, into the company, at 7 company shares for every 200 Krebs shares held by others, subject to approvals.474849
- On 12 Jun 2026, the company signed a global licensing agreement with Bhami's Research Laboratory for its under-the-skin delivery platform, to develop monoclonal antibody medicines for cancer and inflammatory diseases.50
- From 1 to 5 Dec 2025, the US FDA inspected the company's API plant at Tarapur, Maharashtra, and issued a Form 483 (a list of inspection observations) with 3 observations; the company's documents give no outcome.51
Last updated
All 51 sources, each with its page
- 1. Annual report, 14 Jul 2026, page 115
- 2. Annual report, 14 Jul 2026, page 61
- 3. Annual report, 14 Jul 2026, page 115
- 4. Annual report, 14 Jul 2026, page 61
- 5. Earnings call, 14 Aug 2026, page 8
- 6. Annual report, 14 Jul 2026, page 24
- 7. Annual report, 14 Jul 2026, page 23
- 8. Annual report, 14 Jul 2026, page 115
- 9. Annual report, 14 Jul 2026, page 193
- 10. Annual report, 14 Jul 2026, page 115
- 11. Annual report, 14 Jul 2026, page 194
- 12. Annual report, 14 Jul 2026, page 48
- 13. Annual report, 14 Jul 2026, page 26
- 14. Exchange filing, 26 Jun 2026, page 5
- 15. Annual report, 14 Jul 2026, page 18
- 16. Annual report, 14 Jul 2026, page 33
- 17. Investor presentation, 1 Sep 2026, page 23
- 18. Earnings call, 14 Aug 2026, page 4
- 19. Annual report, 14 Jul 2026, page 22
- 20. Annual report, 14 Jul 2026, page 22
- 21. Investor presentation, 1 Sep 2026, page 26
- 22. Earnings call, 14 Aug 2026, page 3
- 23. Investor presentation, 1 Sep 2026, page 26
- 24. Annual report, 14 Jul 2026, page 22
- 25. Investor presentation, 1 Sep 2026, page 14
- 26. Annual report, 14 Jul 2026, page 25
- 27. Investor presentation, 1 Sep 2026, page 24
- 28. Earnings call, 14 Aug 2026, page 3
- 29. Annual report, 14 Jul 2026, page 23
- 30. Annual report, 14 Jul 2026, page 24
- 31. Annual report, 14 Jul 2026, page 23
- 32. Annual report, 14 Jul 2026, page 26
- 33. Annual report, 14 Jul 2026, page 26
- 34. Annual report, 14 Jul 2026, page 26
- 35. Annual report, 14 Jul 2026, page 26
- 36. Investor presentation, 1 Sep 2026, page 54
- 37. Investor presentation, 1 Sep 2026, page 40
- 38. Annual report, 14 Jul 2026, page 24
- 39. Annual report, 14 Jul 2026, page 26
- 40. Investor presentation, 1 Sep 2026, page 55
- 41. Earnings call, 14 Aug 2026, page 12
- 42. Earnings call, 14 Aug 2026, page 11
- 43. Earnings call, 14 Aug 2026, page 13
- 44. Earnings call, 14 Aug 2026, page 14
- 45. Exchange filing, 7 Jul 2026, page 1
- 46. Exchange filing, 7 Jul 2026, page 1
- 47. Exchange filing, 26 Jun 2026, page 1
- 48. Exchange filing, 26 Jun 2026, page 3
- 49. Exchange filing, 26 Jun 2026, page 4
- 50. Exchange filing, 12 Jun 2026, page 2
- 51. Exchange filing, 5 Dec 2025, page 1
Results
Consolidated; ₹ crore.IPCA Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +10.6%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +68.2%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,788 Crup 16.73%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹424 Crup 38.34%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 15.2%
Revenue by quarter
Peak revenue ₹2,788 Cr, quarter to Jun 2026; lowest ₹2,245 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,355 | 2,245 | 2,247 | 2,309 | 2,557 | 2,393 | 2,388 | 2,788 |
| Net profit | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 |
| Net margin | 10.4% | 12.3% | 2.8% | 10.1% | 11.0% | 15.2% | 12.8% | 15.2% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹9,646 Crup 7.91%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,184 Crup 50.75%
- Net margin
- 12.3%
Revenue by year
Peak revenue ₹9,646 Cr, year to Mar 2026; lowest ₹3,211 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,211 | 3,284 | 3,773 | 4,649 | 5,420 | 5,830 | 6,244 | 7,705 | 8,940 | 9,646 |
| Net profit | 195 | 239 | 442 | 604 | 1,141 | 890 | 479 | 523 | 785 | 1,184 |
| Net margin | 6.1% | 7.3% | 11.7% | 13.0% | 21.1% | 15.3% | 7.7% | 6.8% | 8.8% | 12.3% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.IPCA Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 64% of 2,351 trading days over the last 10 years.
LowestHighest
Its median33.69Industry median28.15
Price to book
At or below today's level on 86% of 1,971 trading days since Nov 2018.
LowestHighest
Its median4.96Industry median2.95
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 62% of 2,466 trading days over the last 10 years.
LowestHighest
Its median0.27%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +7.0% | +54.7% | −31.1% | 0.4% |
| 3 years | +25.8% | +34.3% | −6.5% | 0.3% |
| 5 years | +11.3% | 0.0% | +11.0% | 0.4% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2025.
Mutual fund holdings
159 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 71 of the 95 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 159 funds holding IPCA Laboratories
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 45
- CutCut. Funds that held fewer shares than at the end of the month before.
- 50
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 61
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 2
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 1,81,40,659 | 3.43% | ₹3,495.7 Cr |
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 1,23,48,047 | 3.57% | ₹2,379.5 Cr |
 Axis Midcap FundAxis Mutual Fund | 40,05,425 | 2.30% | ₹771.8 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 31,00,000 | 1.19% | ₹597.4 Cr |
 DSP Midcap FundDSP Mutual Fund | 28,75,353 | 2.84% | ₹554.1 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 25,25,000 | 1.59% | ₹486.6 Cr |
| HDFC Balanced Advantage FundHDFC Mutual Fund | 24,97,123 | 0.47% | ₹481.2 Cr |
| DSP Small Cap FundDSP Mutual Fund | 23,81,239 | 2.14% | ₹458.9 Cr |
 Edelweiss Mid Cap FundEdelweiss Mutual Fund | 18,33,465 | 1.84% | ₹353.3 Cr |
| DSP Healthcare FundDSP Mutual Fund | 15,82,807 | 8.13% | ₹305.0 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.IPCA Laboratories insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Others0 purchases, 1 saleNo purchase₹0.44 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹0.44 Cr3 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
IPCA Laboratories competitors and peers
Pharmaceuticals, 214 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to IPCA Laboratories in market cap. 1 company in its own group left out: one owns more than half of the other, directly or through a company it controls, or one owner more than half of both.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Alkem LaboratoriesALKEM | 60,619 | 28.10 | 4.39 | +13.4% | −5.6% | 16.7% | 16.5% | 1.05% |
 BioconBIOCON | 57,153 | 115.39 | 1.68 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
 Abbott IndiaABBOTINDIA | 55,833 | 34.58 | 11.69 | +6.3% | +11.2% | 35.9% | 39.6% | 2.50% |
 Gland PharmaGLAND | 50,312 | 44.57 | 4.86 | +17.6% | +46.5% | 11.6% | 12.4% | 0.66% |
 Ajanta PharmaAJANTPHARM | 43,233 | 38.10 | 9.55 | +20.2% | +22.0% | 27.3% | 27.2% | 1.73% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,318 | 39.62 | 18.66 | +5.8% | +12.4% | 50.6% | 56.3% | 2.28% |
 Emcure PharmaceuticalsEMCURE | 35,571 | 35.17 | 7.19 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
 Sai Life SciencesSAILIFE | 31,591 | 87.33 | 12.72 | – | – | 15.7% | 18.7% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.IPCA Laboratories dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹6.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 7 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹6.00 |
| 5 Aug 2025 | Final | ₹2.00 |
| 27 Nov 2024 | Interim | ₹2.00 |
| 6 Aug 2024 | Final | ₹2.00 |
| 22 Nov 2023 | Interim | ₹2.00 |
| 22 Nov 2022 | Interim | ₹4.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.IPCA Laboratories announcements
Oct 2026
28 Oct · Analysts
22 Oct · Board meeting
Aug 2026
17 Aug · Analysts
13 Aug · Meeting
IPCA Laboratories share price by year
Each calendar year to 2025.IPCA Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,418.90 | −16.3% | 1,744.05 | 1,268.70 |
| 2024 | 1,695.20 | +52.3% | 1,703.25 | 1,077.70 |
| 2023 | 1,113.15 | +32.0% | 1,149.70 | 675.00 |
| 2022 | 843.10 | −22.2% | 1,099.90 | 843.10 |
| 2021 | 1,083.40 | −1.0% | 1,318.75 | 900.45 |
| 2020 | 1,094.40 | +92.6% | 1,184.05 | 569.18 |
| 2019 | 568.13 | +41.7% | 579.85 | 361.50 |
| 2018 | 401.05 | +34.1% | 403.15 | 277.55 |
| 2017 | 299.15 | +12.2% | 323.23 | 204.40 |
| 2016 | 266.53 | −28.2% | 371.15 | 203.70 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,949.70 | 1,994.00 | 1,938.60 | 1,980.80 | 1,970.33 | 1,89,254 | 55.6% |
| 26 Oct 2026 | 1,953.30 | 1,989.60 | 1,922.00 | 1,938.60 | 1,957.66 | 3,32,626 | 48.3% |
| 23 Oct 2026 | 1,892.00 | 1,979.80 | 1,857.70 | 1,953.30 | 1,918.99 | 3,18,781 | 51.9% |
| 22 Oct 2026 | 1,898.00 | 1,952.00 | 1,884.20 | 1,903.50 | 1,918.58 | 3,27,011 | 49.5% |
| 21 Oct 2026 | 1,810.00 | 1,949.90 | 1,797.60 | 1,918.90 | 1,883.27 | 5,11,090 | 39.2% |
| 19 Oct 2026 | 1,832.60 | 1,853.90 | 1,797.00 | 1,814.50 | 1,827.22 | 1,67,626 | 52.6% |
| 16 Oct 2026 | 1,907.10 | 1,907.10 | 1,813.20 | 1,832.60 | 1,845.22 | 2,15,600 | 50.7% |
| 15 Oct 2026 | 1,888.00 | 1,930.00 | 1,888.00 | 1,913.10 | 1,912.92 | 1,66,493 | 65.7% |
| 14 Oct 2026 | 1,889.90 | 1,929.00 | 1,863.20 | 1,911.60 | 1,889.09 | 2,05,496 | 42.8% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 10 Jan 2022 | Split | 0.5000 | Each share became 2. |
| 22 Mar 2010 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- IPCALAB
- BSE code
- 524494
- ISIN
- INE571A01038
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.ipca.com
- CIN
- L24239MH1949PLC007837
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1949
- Registered office
- 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400067, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, BSE MidCap, Nifty Total Market